Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Strategic Acquisition Broadens Company’s Diagnostic Imaging Product Portfolio

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that it has acquired the balance of the worldwide rights for gadofosveset trisodium, a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent that it currently markets in the United States as ABLAVAR. ABLAVAR is indicated for use in adults with known or suspected peripheral vascular disease to evaluate aortoiliac occlusive disease. Lantheus purchased the worldwide rights in a recent auction of the remaining assets of EPIX Pharmaceuticals. The company already owns exclusive rights to ABLAVAR in the United States, Canada and Australia. Terms of the purchase were not announced. “Securing global ownership of ABLAVAR positions us well for future growth and for possible strategic opportunities and partnerships for the product in new geographic areas.”

“Obtaining the balance of the worldwide ownership of ABLAVAR is part of our strategy to broaden our portfolio of medically important diagnostic imaging products. Our goal is to make this novel blood pool imaging agent available to patients and physicians on an expanded basis,” said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging, Inc. “Securing global ownership of ABLAVAR positions us well for future growth and for possible strategic opportunities and partnerships for the product in new geographic areas.”

Source: Lantheus Medical Imaging, Inc